Lymphoma
Drug research and approvals for lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,700 studies of lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 238 drug trials for it since 2013, FDA has 125 approved and 174 open orphan designations naming it, and the EU has 43 authorised medicines for it.
- Recruiting worldwide: 1,700
- Trials authorized in Canada: 238
- FDA orphan approvals: 125
- EU medicines: 43
- First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That…NCT07948733 · Phase 1 · Cellogen Therapeutics Pvt. Ltd. · starts Oct 26, 2026
- Simulation-Free Single-Fraction Radiation Therapy for Indolent LymphomaNCT07945470 · Not applicable · University Health Network, Toronto · starts Oct 9, 2026
- Multimodal Ultrasound for Lymphoma Classification and Treatment Response PredictionNCT07941063 · Not reported · Chinese PLA General Hospital · starts Jan 1, 2026
- Impact of Vitamin D on Gut Microbiome and Metabolome Among Pediatric Oncology PatientsNCT07938333 · Not reported · Children's Hospital of Orange County · starts Nov 9, 2026
- Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment…NCT07934537 · Phase 4 · Shanghai Tongji Hospital, Tongji University School of Medicine · starts Oct 30, 2025
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute…NCT07936266 · Phase 1 · Sunil G. Iyer · starts Mar 31, 2027
- CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNCT07927816 · Phase 1 · Liping Dou · starts Sep 1, 2026
- The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic…NCT07912684 · Not applicable · Gruppo Italiano Malattie EMatologiche dell'Adulto · starts Nov 10, 2026
- Evaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and LymphomaNCT07914348 · Phase 1 · Leukos Biotech S.L. · starts Aug 7, 2024
Approved 24 of 60
- CyclophosphamideDNA inhibitor
- PrednisoneGlucocorticoid receptor agonist
- RituximabNon-Hodgkin lymphoma · B-lymphocyte antigen CD20 binding agent
- DexamethasoneGlucocorticoid receptor agonist
- Brentuximab vedotinHodgkin disease · Tubulin inhibitor
- IbrutinibMantle-cell lymphoma · Tyrosine-protein kinase BTK inhibitor
- DacarbazineHodgkin disease · DNA inhibitor
- LenalidomideFollicular lymphoma · CRL4(CRBN) E3 ubiquitin ligase inhibitor
- DoxorubicinHodgkin disease · DNA topoisomerase II alpha inhibitor
- VinblastineHodgkin disease · Tubulin inhibitor
- BortezomibMantle-cell lymphoma · 26S proteasome inhibitor
- BleomycinDNA inhibitor
- ObinutuzumabFollicular lymphoma · B-lymphocyte antigen CD20 binding agent
- BendamustineNon-Hodgkin lymphoma · DNA inhibitor
- NivolumabHodgkin disease · Programmed cell death protein 1 inhibitor
- AcalabrutinibMantle-cell lymphoma · Tyrosine-protein kinase BTK inhibitor
- PembrolizumabHodgkin disease · Programmed cell death protein 1 inhibitor
- Polatuzumab vedotinDiffuse large B-cell lymphoma · B-cell antigen receptor complex-associated protein beta chain binding agent
- ZanubrutinibMantle-cell lymphoma · Tyrosine-protein kinase BTK inhibitor
- Yttrium y 90 ibritumomab tiuxetanFollicular lymphoma · B-lymphocyte antigen CD20 binding agent
- MosunetuzumabFollicular lymphoma · T cell surface glycoprotein CD3 binding agent
- TafasitamabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD19 binding agent
- GlofitamabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD20 binding agent
- MethotrexateNon-Hodgkin lymphoma · Dihydrofolate reductase inhibitor
Phase 3 12 of 109
- VincristineTubulin inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- CytarabineDNA inhibitor
- IfosfamideDNA inhibitor
- CisplatinDNA inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- Leucovorin
- SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonist
- BusulfanDNA inhibitor
- Fludarabine
- MitoxantroneDNA topoisomerase II alpha inhibitor
- OxaliplatinDiffuse large B-cell lymphoma · DNA inhibitor
Phase 2 12 of 215
- PentostatinAdenosine deaminase inhibitor
- Bryostatin 1
- TemozolomideDNA inhibitor
- Carfilzomib26S proteasome inhibitor
- BlinatumomabNon-Hodgkin lymphoma · T cell surface glycoprotein CD3 cross-linking agent
- TopotecanDNA topoisomerase I inhibitor
- UCN-01Cyclin-dependent kinase 2 inhibitor
- AtezolizumabDiffuse large B-cell lymphoma · Programmed cell death 1 ligand 1 inhibitor
- DurvalumabDiffuse large B-cell lymphoma · Programmed cell death 1 ligand 1 inhibitor
- ZidovudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- ClofarabineRibonucleoside-diphosphate reductase RR1 inhibitor
- DacetuzumabNon-Hodgkin lymphoma · Tumor necrosis factor receptor superfamily member 5 inhibitor
Phase 1 or earlier 12 of 291
- RifampinBacterial DNA-directed RNA polymerase inhibitor
- Prizloncabtagene autoleucelFollicular lymphoma
- ItraconazoleCytochrome P450 51 inhibitor
- LenvatinibVascular endothelial growth factor receptor inhibitor
- BL22CD22 binding agent
- SpartalizumabProgrammed cell death protein 1 antagonist
- IberdomideCRL4(CRBN) E3 ubiquitin ligase modulator
- AvadomideDiffuse large B-cell lymphoma
- IMM-0306B-cell lymphoma
- KetoconazoleCytochrome P450 51 inhibitor
- MidazolamNon-Hodgkin lymphoma · GABA-A receptor; anion channel positive allosteric modulator
- TrastuzumabNon-Hodgkin lymphoma · Receptor protein-tyrosine kinase erbB-2 inhibitor
How its trials ended
6,428 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 1,774 whose ending is known, 37% met their primary endpoint, 5% missed it and 58% stopped early.
- Completed, result not reported2,03232%
- Ongoing1,83128%
- Status unknown79112%
- Met its primary endpoint66110%
- Stopped: other or unclear4637%
- Stopped: enrollment or feasibility2534%
- Stopped: sponsor or business decision1893%
- Missed its primary endpoint821%
- Stopped: lack of efficacy701%
- Stopped: funding391%
- Stopped: safety17<1%
| Oct 30, 2026 | A phase 2/3 multi-arm, open-label study of MK-1045 in combination with zilovertamab vedotin in participants with relapsed/refractory diffuse large B-cell…MK-1045 / Zilovertamab vedotin (MK-2140) | Merck & Co. (MSD) | Pending |
| Oct 16, 2026 | A phase 3, open label, randomized study comparing the efficacy and safety of odronextamab (REGN1979), an ANTI-CD20 × ANTI-CD3 bispecific antibody, in…Odronextamab (REGN1979) | Regeneron | Pending |
| Aug 11, 2026 | A single-arm, phase 2, open-label, multicenter study to evaluate NX-5948 in adults with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) or small…NX-5948 | Nurix Therapeutics | Pending |
| Jul 23, 2026 | A phase III study to evaluate the efficacy of surovatamig combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (r-chop) in…Surovatamig | AstraZeneca Pharmaceuticals | Pending |
| May 6, 2026 | A phase 3, multiregional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with relapsed/refractory primary central…Tirabrutinib (ONO-4059) / Rituximab (TRUXIMA) / Temozolomide | Ono Pharmaceutical | Pending |
| Apr 29, 2026 | A phase 1/2 open-label, multi-center study to evaluate the safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-cell…GSK5926371 | GSK | Ongoing |
| Apr 16, 2026 | A phase 2/3 randomized, open-label study for MK-1045 in combination with rituximab in participants with 1 l follicular lymphomaMK-1045 / Rituximab | Merck & Co. (MSD) | Ongoing |
| Apr 10, 2026 | A phase 3, randomized, open-label, multicenter study evaluating the efficacy of KITE-753 versus axicabtagene ciloleucel in participants with relapsed and/or…KITE-753 | Kitepharma Inc | Ongoing |
| Apr 9, 2026 | A global stufy of novel agents in paediatric and adolescent replapsed and refractory B-cell Non-Hodgkin lymphomaREGN1979 / ADCT-402 / Etopophos | C17 Council | Pending |
| Mar 11, 2026 | A phase 1/2 open-label, multicenter study evaluating the safety and efficacy of KITE-363 or KITE-753, autologous ANTI-CD19/CD20 car T-cell therapies, in…KITE-753 | Kitepharma Inc | Ongoing |
| Oct 2, 2026 | JaypircaTreatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known… | Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company | Approved |
| May 13, 2026 | BeqalziTreatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including… | BeOne Medicines USA, Inc. | Approved |
| Mar 20, 2026 | OpdivoIn combination with doxorubicin, vinblastine, and dacarbazine (AVD), for the treatment of adult and pediatric patients 12 years and older… | Bristol-Myers Squibb Company | Approved |
| Feb 5, 2026 | YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12… | Kite Pharma, Inc. | Approved |
| Dec 19, 2025 | Lunsumio VeloTreatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy | Genentech, Inc. | Approved |
| Dec 4, 2025 | BreyanziTreatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least 2 prior lines of systemic… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Dec 4, 2025 | BreyanziTreatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least 2 prior lines of systemic… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Dec 4, 2025 | BreyanziTreatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least 2 prior lines of systemic… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Dec 3, 2025 | JaypircaTreatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have… | Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company | Approved |
| Nov 18, 2025 | EpkinlyIn combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) | Genmab US, Inc. | Approved |
| Jun 18, 2025 | MonjuviIn combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) | Incyte Corporation | Approved |
| Jan 16, 2025 | CalquenceIn combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who… | Acerta Pharma, LLC (a member of the AstraZeneca Group) | Approved |
| Aug 7, 2024 | LymphirTreatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic… | Citius Oncology, Inc. | Approved |
| Jun 26, 2024 | EpkinlyTreatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy | Genmab US, Inc. | Approved |
| May 30, 2024 | BreyanziTreatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic… | Juno Therapeutics, Inc. | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA